# A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma

> **NCT05160805** · PHASE1 · COMPLETED · sponsor: **ONL Therapeutics** · enrollment: 25 (actual)

## Conditions studied

- Open Angle Glaucoma

## Interventions

- **DRUG:** ONL1204 Ophthalmic solution (Dose A)
- **DRUG:** ONL1204 Ophthalmic solution (Dose B)
- **PROCEDURE:** Sham procedure

## Key facts

- **NCT ID:** NCT05160805
- **Lead sponsor:** ONL Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-02
- **Primary completion:** 2024-04-09
- **Final completion:** 2024-04-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05160805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05160805, "A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05160805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*